ETF investors in biotechnology stocks may be rattled by the nose-dive of the first heavyweight out of the earnings gate. IShares Nasdaq Biotechnology (IBB), the $10 billion biotech exchange traded fund, has lost 0.8% in the past three trading sessions as Illumina (ILMN) stumbled. Ahead of Celgene's (CELG) and Biogen's (BIIB) reports this week, IBD spoke to Tushar Yadava, an iShares investment strategist, on whether the biotech sector has room to
No comments:
Post a Comment